Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

08:36pm	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI

Market Cap	63.66B 54.91B 51.65B 47.06B 88.49B 6,042B 88.97B 611B 238B 3,073B 239B 234B 10,190B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 69.84B 65.69B 59.85B 113B 7,684B 113B 777B 302B 3,909B 304B 297B 12,960B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

08:36pm	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/09/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/08/25	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
30/06/25	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
12/02/25	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
19/10/24	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
27/08/24	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
06/05/20	Trump franchit le Rubicon

Actavis PLC Stock NYSE

Stocks

US00507K1034

Pharmaceuticals

Valuation : Actavis PLC

Latest news : Actavis PLC

Press Releases : Actavis PLC

News in other languages : Actavis PLC

Managers and Directors : Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	01/12/2016
Robert Michael PSD	President	55	08/05/2020

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	08/05/2020
Scott Reents BRD	Director/Board Member	-	08/05/2020
Ryan Quigley BRD	Director/Board Member	-	08/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.28%	-6.97%	+58.34%	+109.31%	1,031B
JOHNSON & JOHNSON	+2.01%	-0.68%	+53.07%	+67.73%	641B
ABBVIE INC.	+1.39%	-1.71%	+23.57%	+76.91%	453B
ROCHE HOLDING AG	-1.50%	-6.18%	+33.50%	+33.50%	349B
NOVARTIS AG	+6.25%	+3.31%	+29.46%	+46.64%	290B
ASTRAZENECA PLC	-0.07%	-1.22%	+1.46%	+12.19%	252B
AMGEN INC.	+1.92%	-1.29%	+52.28%	+70.91%	232B
NOVO NORDISK A/S	+0.51%	-1.79%	-18.09%	-53.86%	201B
GILEAD SCIENCES, INC.	+2.45%	+2.17%	+32.71%	+96.03%	181B
Average	+1.09%	-2.98%	+29.59%	+51.04%	403.31B
Weighted average by Cap.	+0.99%	-3.97%	+38.53%	+66.75%

	2018	2019
Net sales	15.79B 13.62B 12.81B 11.67B 21.95B 1,498B 22.06B 151B 58.94B 762B 59.27B 57.99B 2,527B	16.09B 13.88B 13.05B 11.89B 22.36B 1,527B 22.49B 154B 60.07B 777B 60.41B 59.1B 2,575B
Net income	-5.1B -4.4B -4.14B -3.77B -7.08B -484B -7.12B -48.89B -19.03B -246B -19.13B -18.72B -816B	-5.27B -4.55B -4.28B -3.9B -7.33B -500B -7.37B -50.56B -19.68B -254B -19.79B -19.36B -844B
Net Debt	21.89B 18.88B 17.76B 16.18B 30.43B 2,078B 30.59B 210B 81.73B 1,057B 82.19B 80.41B 3,504B	17.3B 14.93B 14.04B 12.79B 24.05B 1,642B 24.18B 166B 64.61B 835B 64.97B 63.56B 2,770B

End-of-day quote NYSE
- ^USD	-